2 Information about abemaciclib

2 Information about abemaciclib

Information about abemaciclib

Marketing authorisation

Abemaciclib (Verzenios, Eli Lilly) is indicated for the treatment of 'women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with … fulvestrant … in women who have received prior endocrine therapy. In pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.'

Dosage in the marketing authorisation

The recommended dose of abemaciclib is 150 mg orally twice daily when used with endocrine therapy. Management of some adverse reactions may need dose interruption or dose reduction – see the summary of product characteristics. It should be taken continuously as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.


£2,950 for 56 × 150 mg tablets (excluding VAT, British national formulary online [accessed March 2019]).

The company has a commercial arrangement. This makes abemaciclib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)